The leading edge of Hetero Group, Hetero Biopharma, is steadily establishing itself as a path breaking Biosimilar developer. As a strong R&D driven company offering some of the blockbuster Biosimilar Drugs, we at Hetero Biopharma are bringing about a paradigm shift in the way patients suffering from various chronic conditions are treated.
Read more >>>
-
Hetero Biopharma organized Cancer Survivors day gatherings across Asia and Africa
-
3rd Live interactive webinar session for Nephrologists connecting the continents by Hetero Biopharma
-
Hetero Biopharma launched 2 biosimilars Derise, Rilast in Nepal.
-
Hetero Biopharma launched Darbepoetin alfa in Dhaka, Bangladesh under the brand name ‘Darbesis’.
-
Customized Key Opinion Meet organized for Nephrologists at Phnom Penh Cambodia
-
Hetero Biopharma participated in 16th Joint AFRAN/APNA Annual scientific conference at Mombasa Kenya
-
Hetero Biopharma participated in 4th Annual Conference of Cambodian Association of Nephrology
-
Hetero Biopharma launched Rilast (Rituximab) in Georgia – the first Biosimilar Rituximab in Georgia
-
Hetero Biopharma launched Derise in Sri Lanka- Rise of first Darbepoetin in Sri Lanka
-
Hetero Biopharma Organised INCON 2019 (International Conclave of Oncology) at Hyderabad
-
Biopharma – Awarded in the category of “Excellence in Pharma Packaging”
-
Hetero Biopharma organised Paramedical Staff Debut education programme @ Uganda
-
Hetero Biopharma participated in 7th Conference of Myanmar society of Haematology 2019
-
Biopharma participated in Sri Lanka College of Haematologists Session 2019
-
Hetero Biopharma organised CME programme at Phnom Penh, Cambodia.
-
Hetero Biopharma launches ‘RILAST,’ the biosimilar Rituximab in Georgia.
-
Hetero Biopharma launches RILAST - 1st Rituximab Biosimilar in Uzbekistan
-
Hetero Biopharma co-hosted and participated in BioAsia 2020 for the fourth consecutive year!!
With leadership in chemical therapeutics,
Hetero continues to lead from the front in the development and manufacturing of Biopharmaceuticals using novel technologies.
Genesis and Onwards
2009
Conceptualized with the identification of Key Biosimilars
2011
Completion of state-of-the-art R&D and Biologics manufacturing facility
2014
Launch of Darbepoetin Alfa - First Biosimilar product of Hetero Biopharma
2nd Company in the world to launch Biosimilar Darbepoetin
2015
Launch of Rituximab Injection - 2nd Biosimilar and 1st MAB of Hetero Biopharma
Expansion of the Biosimilar facility to cater the demands of Global markets
2016
Launch of Bevacizumab Injection - our 3rd Biosimilar product
GMP accreditation by PIC/s member country
Entry in to global markets
2017
Launch of Adalimumab Injection – our 4th Biosimilar product
Expansion of the new manufacturing block completed
2018
Clinical evaluation of anti HER 2 mAb in progress
Progress in filing of biosimilars in regulated markets
2019
1st company to launch Adalimumab autoinjector pen in India for better patient compliance
1st company in Africa to market Biosimilars with a dedicated team with a mission of REACHing every needy patient
Our Core Competencies
We are constantly evolving and expanding our competencies, relentlessly and rapidly.
Our Biosimilars
We strive to make complex Bio therapeutics available and more accessible to patients across the globe.
Our Global Presence
Hetero Biopharma Insignia
The Hetero Biopharma Insignia is an apt interplay of a DNA and an hourglass. Together, they represent 'life' and 'time' thereby signifying Hetero's foray into modern biopharmaceuticals by not just offering high quality human biotechnology products but also focussing on their early commercialisation.
The colours Orange and Deep Yellow are obvious representation of the 'daybreak' and signify hope and life. The Grey colour signifies our intent to apply knowledge and expertise for better outcomes.
